U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Monday.Shares of Novo Nordisk A/S (NYSE:NVO) fell sharply in today's pre-market trading after Evoke Phase 3 trials data showed that GLP-1 drugs did not demonstrate statistically significant reduction in Alzheimer’s disease progression.Novo Nordisk shares dipped 9.3% to $43.22 in pre-market trading.Here are some other stocks moving lower in pre-market trading.Geospace Technologies Corp (NASDAQ:GEOS) shares tumbl ...

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Monday.Shares of Novo Nordisk A/S (NYSE:NVO) fell sharply in today's pre-market trading after Evoke Phase 3 trials data showed that GLP-1 drugs did not demonstrate statistically significant reduction in Alzheimer’s disease progression.Novo Nordisk shares dipped 9.3% to $43.22 in pre-market trading.Here are some other stocks moving lower in pre-market trading.Geospace Technologies Corp (NASDAQ:GEOS) shares tumbl ...

Shares of Novo Nordisk fell sharply on Monday after the company announced that a high-profile trial testing whether its oral semaglutide medicine could slow the progression of Alzheimer's disease had ... ...

核心观点 - 诺和诺德股价因阿尔茨海默病药物试验失败而大幅下跌至2021年7月以来最低水平 [1] 股价表现 - 哥本哈根股价早盘跌幅超过12%，随后小幅回升至273.35丹麦克朗（42.25美元），跌幅约10.3% [1] - 公司股价自2025年初以来累计下跌57.2%，较2024年6月峰值（超过1000丹麦克朗）下跌逾72% [4] 临床试验结果 - 两项大型试验（覆盖3,808名成人）未达到主要终点，显示司美格鲁肽未能显著减缓阿尔茨海默病进展 [2] - 认知评估表明接受司美格鲁肽治疗的患者与安慰剂组相比疾病进展无显著减缓 [2] - 试验对象为55至85岁患有轻度认知障碍或轻度阿尔茨海默病痴呆的患者 [3] - 两项试验中阿尔茨海默病相关生物标志物均显示改善 [3] 公司后续行动 - 将终止原计划为期一年的研究延长部分 [3]

Oral semaglutide—the ingredient in obesity and diabetes drugs Ozempic and Wegovy—didn't slow Alzheimer's disease in two late-stage clinical trials. ...

Novo Nordisk's stock tumbles after its oral GLP-1 drug failed to show much benefit over a placebo against Alzheimer's. ...

Oral semaglutide—the ingredient in obesity and diabetes drugs Ozempic and Wegovy—didn't slow Alzheimer's disease in two late-stage clinical trials. ...

The Novo Nordisk A/S headquarters in Bagsvaerd, Denmark, on Wednesday, Nov. 5, 2025.Shares of Novo Nordisk on Monday fell as much 11% after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer's disease failed to meet its main goal.The trial tested whether semaglutide -- the active ingredient in Novo's blockbuster diabetes and weight loss drugs Ozempic and Wegovy -- helped slow progression for Alzheimer's disease. This is breaking news. Please refresh for updates. ...

公司股价表现 - 礼来公司股价在盘前交易时段一度大幅下跌5.5% [1] - 股价下跌主要受诺和诺德公司股价大跌影响 [1]

Novo Nordisk said on Monday an older oral version of its semaglutide drug failed to meet its main goal in late-stage trials testing whether the medicine can slow cognitive decline in Alzheimer's patie... ...